Eli Lilly (LLY)
(Real Time Quote from BATS)
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
Lilly (LLY) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge.
Goldilocks Econ Data Presides Over Pre-Market
by Mark Vickery
We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.
Eli Lilly (LLY) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others
by Zacks Equity Research
Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
by Zacks Equity Research
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
by Zacks Equity Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $346.39 in the latest trading session, marking a +1.22% move from the prior day.
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
by Zacks Equity Research
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds
by Kinjel Shah
FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $352.01, marking a -1.6% move from the previous day.
BAYRY or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAYRY vs. LLY: Which Stock Is the Better Value Option?
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.